Tenaya Therapeutics enters $75M at-the-market equity sales agreement with SVB Securities

Tenaya Therapeutics, Inc.

Aggregate sales proceeds up to $75M from common stock sold through ATM program.
SVB Securities receives 3.0% commission on gross proceeds as sales agent.
Company sets parameters including price and volume; no obligation to sell shares.
Shares issued under shelf registration statement filed August 10, 2022.
Agreement can be terminated by either party on 10 days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.